COMPANY PROFILE

Novelty Nobility

Explore full profile

A private biotech company focused on the research of novel angiogenesis targets and develop antibody-based therapeutics

Seongnam-si, South KoreaFounded 2017Biotech & Life Sciences

Valuation $250–500M Last recorded · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Novelty Nobility

Novelty Nobility Inc. is a private biotech company headquartered in South Korea, specializing in the design, discovery, optimization, and early-stage development of next-generation antibodies. The company focuses on creating therapeutic antibodies, antibody drug conjugates (ADCs), and ADC linker technologies to address drug resistance, primarily in oncology. However, they also explore other medical fields such as ophthalmology and autoimmune diseases to meet unmet medical needs.

The company serves pharmaceutical and biotechnology firms looking for innovative solutions in antibody development. Operating in the highly specialized biotech market, Novelty Nobility employs a business model centered around research and development, partnering with other firms for clinical trials and commercialization. Revenue is generated through licensing agreements, research collaborations, and milestone payments.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2017
Headquarters: Seongnam-si, South Korea
Employees: 10
Open positions: 2
Dealroom signal: 36.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Sep 2025	$0	—	Koas	↗
SERIES COther financing	Nov 2024	$62M	$250M	Undisclosed	↗

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Novelty Nobility website traffic

Latest recorded traffic for Novelty Nobility is 2.5K monthly website visits, down 7.4% over the last three months. Novelty Nobility's team grew 25% over the past year.

Latest monthly visits2.5K 3-month web change-7.4% 1-year team growth+25%

Monthly website visitsFeb 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

( , 1)South Korea, Gyeonggi-do, Seongnam-si, Bundang-gu, Pangyo-dong, 621번지 6층 KR · Other · Jun 25, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational	5	$35M	$90M
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational